Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC By Ogkologos - June 6, 2025 682 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from integrated analyses of sotorasib clinical efficacy biomarkers in the CodeBreaK 100 and CodeBreaK 200 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Liquid Biopsy May Predict Risk of Breast Cancer Returning Years Later August 15, 2018 New Immunotherapy Option Approved for Cervical Cancer, Rare Lymphoma August 2, 2018 Philanthropist Simon Collins: “I realised I could make a difference by... September 6, 2021 How Receiving My Own Cancer Diagnosis Changed My Perspective on Caring... August 25, 2020 Load more HOT NEWS Promising Results Are Provided by Tebentafusp in Metastatic Uveal Melanoma Immunotherapy Drug Tebentafusp Improves Survival in Advanced Uveal Melanoma FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with... Toothbrushes and ctDNA: Exciting early detection concepts from new teams formed...
